Fragile X Syndrome
Fragile X
syndrome may be a genetic condition that causes a variety of developmental problems including learning disabilities and cognitive impairment. Usually, males are more severely suffering from this disorder than females.Affected individuals usually have delayed development of speech and language by age 2. Most males with fragile X
syndrome have mild to moderate intellectual disability, while about one-third of affected females are intellectually disabled. Children with fragile X
syndrome can also have
anxiety and hyperactive behavior like fidgeting or impulsive actions. They may have attention deficit disorder (ADD), which incorporates an impaired ability to take care of attention and difficulty that specialize in specific tasks. Around 33% of individuals with delicate X condition have highlights of mental imbalance range issue that influence correspondence and social cooperation.
Seizures happen in around 15 percent of guys and around 5 percent of females with delicate X syndrome.Most guys and about half females with delicate X disorder have trademark physical highlights that become progressively evident with age. These highlights incorporate an all-encompassing and restricted face, enormous ears, a conspicuous jaw and temple, abnormally adaptable fingers, level feet, and in guys, developed balls (macroorchidism) after adolescence.Males who have FXS usually have some degree of
intellectual disability that can range from mild to severe. Females with FXS can have normal intelligence or a point of intellectual disability
High Impact List of Articles
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Inflammasome activation markers are independently associated with hypoalphalipoproteinemia in a Mexican-Mestizo population
Aida Medina-Urrutia, Carlos Posadas-Romero, Esteban Jorge-Galarza, Angel R Lopez-Uribe, del Carmen Gonzalez-Salazara and Juan G Juarez-Rojas
Research Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Macrolide therapy in cystic fibrosis: new developments in clinical use
K Frayman,P Robinson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Macrolide therapy in cystic fibrosis: new developments in clinical use
K Frayman,P Robinson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Recombinant von Willebrand factor: is this the answer for treatment of von Willebrand disease? ***Recombinant VWF treatment
Steve Keeney
Editorial: Clinical Investigation
-
Recombinant von Willebrand factor: is this the answer for treatment of von Willebrand disease? ***Recombinant VWF treatment
Steve Keeney
Editorial: Clinical Investigation
Relevant Topics in Clinical